Neuroprotective Effects of Ginkgo biloba Extract Against Beta-amyloid Peptide-induced Toxicity in Hippocamal Neurons

ZHANG Hua-jun; WAN Qian; XU Tian-shu

doi:10.13422/j.cnki.syfjx.2011.02.058

您当前的位置：

首页 >

文章列表页 >

Neuroprotective Effects of Ginkgo biloba Extract Against Beta-amyloid Peptide-induced Toxicity in Hippocamal Neurons

更新时间：2024-09-23

- Neuroprotective Effects of Ginkgo biloba Extract Against Beta-amyloid Peptide-induced Toxicity in Hippocamal Neurons
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 17, Issue 2, Pages: 209-212(2011)
- 作者机构：
  
  南京大学医学院附属鼓楼医院中西医结合科
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2011.02.058
  CLC： R285.5
- Published：2011
- 稿件说明：
移动端阅览
[1]张华军,万茜,徐天舒.银杏叶提取物对Aβ诱导神经毒性的保护作用[J].中国实验方剂学杂志,2011,17(02):209-212.

ZHANG Hua-jun, WAN Qian, XU Tian-shu. Neuroprotective Effects of Ginkgo biloba Extract Against Beta-amyloid Peptide-induced Toxicity in Hippocamal Neurons[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(2): 209-212.
[1]张华军,万茜,徐天舒.银杏叶提取物对Aβ诱导神经毒性的保护作用[J].中国实验方剂学杂志,2011,17(02):209-212. DOI： 10.13422/j.cnki.syfjx.2011.02.058.

ZHANG Hua-jun, WAN Qian, XU Tian-shu. Neuroprotective Effects of Ginkgo biloba Extract Against Beta-amyloid Peptide-induced Toxicity in Hippocamal Neurons[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(2): 209-212. DOI： 10.13422/j.cnki.syfjx.2011.02.058.

摘要

目的:研究不同剂量银杏叶（ginkgo biloba extract

EGb761）对Aβ诱导神经元损伤的影响。方法:取高、中、低剂量的EGb761质量浓度分别为100

1 mg·L-1预处理Aβ1-42干预的神经元

检测神经元活力、凋亡率及NeuN染色的变化。结果:与Aβ组相比

高和低剂量EGb761组的神经元活力和NeuN+细胞数存在显著差异（P<0.05）

而中剂量EGb761组神经元活力和NeuN+细胞数均存在极显著差异（P<0.01）;中剂量EGb761组的对神经元凋亡的保护作用优于高、低剂量EGb761组。结论:高、中、低剂量组银杏叶制剂均可提高损伤海马神经元活力、提高NeuN+细胞数

降低神经元凋亡率;尤以中剂量组显著。提示采用预处理的给药方式可保护Aβ诱导的神经元损伤。

Abstract

Objective: To study whether different doses（high

medium

and low doses） Ginkgo biloba extract（EGb761） play a role in neuroprotectoion against beta-amyloid peptide-induced neuronal toxicity.Method: Hippocamal neurons was stimulated with beta-amyloid peptide

three doses EGb761（100

1 mg·L-1） were pre-incubated in injured hippocampal neurons.Neurons viability and apoptosis rate and number of NeuN + cell were detected.Result:There were statistically significant difference in neuronal viability

apoptosis rate and NeuN + cell between Aβ group and three doses EGb761 group（all P<0.05）.Compared with Aβ group

neuronal viability and NeuN + cell of medium-dose group was significant higher and apoptosis rate was significant lower（all P<0.01）.Conclusion:Three doses EGb761 groups increase injured neuronal viability and NeuN + cell and reduce neuronal apoptosis rate

medium-dose group has best neuroprotective effects.EGb761 plays an important role in neuroprotection of beta-amyloid peptide-induced neuronal toxicity.

关键词

Keywords

references

Views

196

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Modified Buwangsan Ameliorates Cognitive Dysfunction in Rat Model of Type 2 Diabetes Mellitus by Regulating Autophagy in Hippocampus via PI3K/Akt/mTOR Pathway

Protective Effect and Mechanism of Anmeidan against Neuronal Damage in Rat Model of Sleep Deprivation Based on Hippocampal Neuroinflammation

Effect of Artemisinin and Its Derivatives in Treatment of Nervous System Diseases： A Review

Neuroprotective Effect of Ginsenoside Rb₁ on Lipopolysaccharide-induced Neuroinflammation in Mice Based on PI3K/Akt Signaling Pathway

Related Author

ZHANG Hua-jun

WAN Qian

XU Tian-shu

YANG Jie

LIU Tonghua

LIU Wei

WU Lili

QIN Lingling

Related Institution

Science and Technology Department， Beijing University of Chinese Medicine

Dongfang Hospital， Beijing University of Chinese Medicine

Key Laboratory of Health Preservation and Rehabilitation， Ministry of Education， Beijing University of Chinese Medicine

Hubei University of Chinese Medicine

Hubei Shizhen Laboratory

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰